Showing 3531-3540 of 4262 results for "".
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- DermaSensor Device Can Help Detect Skin Cancer Across Skin Toneshttps://practicaldermatology.com/news/dermasensor-device-can-help-detect-skin-cancer-across-skin-tones/2461924/DermaSensor's handheld Elastic Scattering Spectroscopy (ESS) device can help detect skin cancer in patients across different Fitzpatrick skin types, according to new research presented at the 2023 American Academy of Dermatology (AAD) Innovation Academy meeting. DermaSensor is desig
- The Dermatology Practice of the Future: AI-Powered Piction Health Dermatology Launches in Massachusettshttps://practicaldermatology.com/news/the-dermatology-practice-of-the-future-ai-powered-piction-health-dermatology-launches-in-mass/2461923/Piction Health Dermatology, an AI-enabled dermatology virtual clinic, is now open for Massachusetts residents. Piction's virtual clinic merges artificial intelligence (AI) with the expertise of board-certified dermatologists. Patients complete a short medical in
- August Is Psoriasis Action Month: Experts Offer Treatment Tipshttps://practicaldermatology.com/news/august-is-psoriasis-action-month-experts-offer-treatment-tips/2461915/August is Psoriasis Action Month and serves as a good time to make sure that your patients are being adequately treated with available therapies, psoriasis experts tell DermWire. Psoriasis is common, affecting 7.5 million in the US, one-third of whom are candidates for either
- A Clinician's Guide to Alopecia: Diagnosis, Treatment, and Preventionhttps://practicaldermatology.com/news/a-clinicians-guide-to-alopecia-diagnosis-treatment-and-prevention/2461898/Hair loss, also known as alopecia, is a prevalent condition that affects people across every demographic.1 Unlike other skin issues that may remain unnoticed for extended periods, hair loss is often immediately apparent to the patient. Recently, alopecia has gained significant media at
- FDA Approves Verrica Pharmaceuticals’ YCANTH for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-verrica-pharmaceuticals-ycanth-for-molluscum-contagiosum/2461882/The U.S. Food and Drug Administration (FDA) has given its nod to Verrica Pharmaceuticals Inc.’s YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients aged two and older. "It's the only topical FDA-approved therapy
- Study: DermaSensor Correctly Identifies 96.2% of Melanomas in Senior Citizenshttps://practicaldermatology.com/news/study-dermasensor-correctly-identifies-962-of-melanomas-in-senior-citizens/2461863/DermaSensor correctly identified 96.2% of melanomas in patients 65 and older, according to a sub-analysis of the DERM-ASSESS III study data of Medicare-eligible patients that was presented at the Annual American Dermoscopy Meeting. The sensitivity of the DermaSensor device for melanoma
- GlobalSkin’s GRIDD Study to Measure True Impact of Skin Diseases Across the Globehttps://practicaldermatology.com/news/globalskins-gridd-study-to-measure-true-impact-of-skin-diseases-across-the-globe/2461856/The International Alliance of Dermatology Patient Organizations (GlobalSkin), in partnership with Cardiff University (UK), and University Medical Centre Hamburg-Eppendorf (Germany), launched the Global Research on the
- Exosome News: ExoCoBio Completes Acquisition of Benevhttps://practicaldermatology.com/news/exosome-news-exocobio-completes-acquisition-of-benev/2461855/ExoCoBio has acquired a majority ownership in BENEV, a global medical aesthetic company that produces growth factor-based skincare products. ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publicati
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra